nodes	percent_of_prediction	percent_of_DWPC	metapath
Glycopyrrolate—Affect lability—Betamethasone—psoriatic arthritis	0.00582	0.00582	CcSEcCtD
Glycopyrrolate—Cystitis noninfective—Methotrexate—psoriatic arthritis	0.00579	0.00579	CcSEcCtD
Glycopyrrolate—Cystitis—Methotrexate—psoriatic arthritis	0.00573	0.00573	CcSEcCtD
Glycopyrrolate—Abdominal distension—Triamcinolone—psoriatic arthritis	0.00567	0.00567	CcSEcCtD
Glycopyrrolate—Abdominal distension—Methylprednisolone—psoriatic arthritis	0.00566	0.00566	CcSEcCtD
Glycopyrrolate—Irritability—Dexamethasone—psoriatic arthritis	0.00565	0.00565	CcSEcCtD
Glycopyrrolate—Irritability—Betamethasone—psoriatic arthritis	0.00565	0.00565	CcSEcCtD
Glycopyrrolate—Cardiac arrest—Dexamethasone—psoriatic arthritis	0.00562	0.00562	CcSEcCtD
Glycopyrrolate—Cardiac arrest—Betamethasone—psoriatic arthritis	0.00562	0.00562	CcSEcCtD
Glycopyrrolate—Mood swings—Betamethasone—psoriatic arthritis	0.0056	0.0056	CcSEcCtD
Glycopyrrolate—Mood swings—Dexamethasone—psoriatic arthritis	0.0056	0.0056	CcSEcCtD
Glycopyrrolate—Dry skin—Betamethasone—psoriatic arthritis	0.00542	0.00542	CcSEcCtD
Glycopyrrolate—Dry skin—Dexamethasone—psoriatic arthritis	0.00542	0.00542	CcSEcCtD
Glycopyrrolate—Bladder pain—Methotrexate—psoriatic arthritis	0.00536	0.00536	CcSEcCtD
Glycopyrrolate—Upper respiratory tract infection—Triamcinolone—psoriatic arthritis	0.00524	0.00524	CcSEcCtD
Glycopyrrolate—Affect lability—Prednisone—psoriatic arthritis	0.00507	0.00507	CcSEcCtD
Glycopyrrolate—Infestation NOS—Methylprednisolone—psoriatic arthritis	0.00501	0.00501	CcSEcCtD
Glycopyrrolate—Infestation—Methylprednisolone—psoriatic arthritis	0.00501	0.00501	CcSEcCtD
Glycopyrrolate—Irritability—Prednisone—psoriatic arthritis	0.00492	0.00492	CcSEcCtD
Glycopyrrolate—Cardiac arrest—Prednisone—psoriatic arthritis	0.0049	0.0049	CcSEcCtD
Glycopyrrolate—Mood swings—Prednisone—psoriatic arthritis	0.00488	0.00488	CcSEcCtD
Glycopyrrolate—Sweating—Methylprednisolone—psoriatic arthritis	0.00481	0.00481	CcSEcCtD
Glycopyrrolate—Epistaxis—Triamcinolone—psoriatic arthritis	0.00474	0.00474	CcSEcCtD
Glycopyrrolate—Dry skin—Prednisone—psoriatic arthritis	0.00472	0.00472	CcSEcCtD
Glycopyrrolate—Hyperglycaemia—Dexamethasone—psoriatic arthritis	0.00461	0.00461	CcSEcCtD
Glycopyrrolate—Hyperglycaemia—Betamethasone—psoriatic arthritis	0.00461	0.00461	CcSEcCtD
Glycopyrrolate—Rhinitis—Triamcinolone—psoriatic arthritis	0.00452	0.00452	CcSEcCtD
Glycopyrrolate—Rhinitis—Methylprednisolone—psoriatic arthritis	0.00451	0.00451	CcSEcCtD
Glycopyrrolate—Abdominal distension—Prednisone—psoriatic arthritis	0.00448	0.00448	CcSEcCtD
Glycopyrrolate—Anaphylactoid reaction—Methotrexate—psoriatic arthritis	0.00445	0.00445	CcSEcCtD
Glycopyrrolate—Connective tissue disorder—Methylprednisolone—psoriatic arthritis	0.00442	0.00442	CcSEcCtD
Glycopyrrolate—Erythema—Prednisolone—psoriatic arthritis	0.00427	0.00427	CcSEcCtD
Glycopyrrolate—Cardiac disorder—Methylprednisolone—psoriatic arthritis	0.00418	0.00418	CcSEcCtD
Glycopyrrolate—Irritability—Methotrexate—psoriatic arthritis	0.00411	0.00411	CcSEcCtD
Glycopyrrolate—Erectile dysfunction—Prednisone—psoriatic arthritis	0.0041	0.0041	CcSEcCtD
Glycopyrrolate—Mood swings—Methotrexate—psoriatic arthritis	0.00408	0.00408	CcSEcCtD
Glycopyrrolate—Mediastinal disorder—Methylprednisolone—psoriatic arthritis	0.00406	0.00406	CcSEcCtD
Glycopyrrolate—Vision blurred—Prednisolone—psoriatic arthritis	0.00402	0.00402	CcSEcCtD
Glycopyrrolate—Hyperglycaemia—Prednisone—psoriatic arthritis	0.00402	0.00402	CcSEcCtD
Glycopyrrolate—Mental disorder—Methylprednisolone—psoriatic arthritis	0.00394	0.00394	CcSEcCtD
Glycopyrrolate—Erythema—Triamcinolone—psoriatic arthritis	0.00393	0.00393	CcSEcCtD
Glycopyrrolate—Malnutrition—Methylprednisolone—psoriatic arthritis	0.00392	0.00392	CcSEcCtD
Glycopyrrolate—Erythema—Methylprednisolone—psoriatic arthritis	0.00392	0.00392	CcSEcCtD
Glycopyrrolate—Dysgeusia—Triamcinolone—psoriatic arthritis	0.00384	0.00384	CcSEcCtD
Glycopyrrolate—Convulsion—Prednisolone—psoriatic arthritis	0.0037	0.0037	CcSEcCtD
Glycopyrrolate—Hypertension—Prednisolone—psoriatic arthritis	0.00369	0.00369	CcSEcCtD
Glycopyrrolate—Abdominal discomfort—Methotrexate—psoriatic arthritis	0.00357	0.00357	CcSEcCtD
Glycopyrrolate—Erythema—Dexamethasone—psoriatic arthritis	0.00356	0.00356	CcSEcCtD
Glycopyrrolate—Erythema—Betamethasone—psoriatic arthritis	0.00356	0.00356	CcSEcCtD
Glycopyrrolate—Connective tissue disorder—Prednisone—psoriatic arthritis	0.0035	0.0035	CcSEcCtD
Glycopyrrolate—Anaphylactic shock—Prednisolone—psoriatic arthritis	0.00348	0.00348	CcSEcCtD
Glycopyrrolate—Oedema—Prednisolone—psoriatic arthritis	0.00348	0.00348	CcSEcCtD
Glycopyrrolate—Dysuria—Methotrexate—psoriatic arthritis	0.00348	0.00348	CcSEcCtD
Glycopyrrolate—Upper respiratory tract infection—Methotrexate—psoriatic arthritis	0.00346	0.00346	CcSEcCtD
Glycopyrrolate—Erectile dysfunction—Methotrexate—psoriatic arthritis	0.00343	0.00343	CcSEcCtD
Glycopyrrolate—Convulsion—Triamcinolone—psoriatic arthritis	0.0034	0.0034	CcSEcCtD
Glycopyrrolate—Tachycardia—Prednisolone—psoriatic arthritis	0.0034	0.0034	CcSEcCtD
Glycopyrrolate—Convulsion—Methylprednisolone—psoriatic arthritis	0.00339	0.00339	CcSEcCtD
Glycopyrrolate—Hypertension—Triamcinolone—psoriatic arthritis	0.00339	0.00339	CcSEcCtD
Glycopyrrolate—Hypertension—Methylprednisolone—psoriatic arthritis	0.00338	0.00338	CcSEcCtD
Glycopyrrolate—Hyperhidrosis—Prednisolone—psoriatic arthritis	0.00337	0.00337	CcSEcCtD
Glycopyrrolate—Pneumonia—Methotrexate—psoriatic arthritis	0.00334	0.00334	CcSEcCtD
Glycopyrrolate—Infestation NOS—Methotrexate—psoriatic arthritis	0.00332	0.00332	CcSEcCtD
Glycopyrrolate—Infestation—Methotrexate—psoriatic arthritis	0.00332	0.00332	CcSEcCtD
Glycopyrrolate—Drowsiness—Methotrexate—psoriatic arthritis	0.00332	0.00332	CcSEcCtD
Glycopyrrolate—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—psoriatic arthritis	0.00331	0.00331	CcSEcCtD
Glycopyrrolate—Flushing—Prednisone—psoriatic arthritis	0.00331	0.00331	CcSEcCtD
Glycopyrrolate—Dry mouth—Triamcinolone—psoriatic arthritis	0.00327	0.00327	CcSEcCtD
Glycopyrrolate—Confusional state—Methylprednisolone—psoriatic arthritis	0.00322	0.00322	CcSEcCtD
Glycopyrrolate—Oedema—Triamcinolone—psoriatic arthritis	0.0032	0.0032	CcSEcCtD
Glycopyrrolate—Anaphylactic shock—Triamcinolone—psoriatic arthritis	0.0032	0.0032	CcSEcCtD
Glycopyrrolate—Anaphylactic shock—Methylprednisolone—psoriatic arthritis	0.0032	0.0032	CcSEcCtD
Glycopyrrolate—Infection—Triamcinolone—psoriatic arthritis	0.00318	0.00318	CcSEcCtD
Glycopyrrolate—Sweating—Methotrexate—psoriatic arthritis	0.00318	0.00318	CcSEcCtD
Glycopyrrolate—Infection—Methylprednisolone—psoriatic arthritis	0.00318	0.00318	CcSEcCtD
Glycopyrrolate—Insomnia—Prednisolone—psoriatic arthritis	0.00315	0.00315	CcSEcCtD
Glycopyrrolate—Nervous system disorder—Methylprednisolone—psoriatic arthritis	0.00314	0.00314	CcSEcCtD
Glycopyrrolate—Epistaxis—Methotrexate—psoriatic arthritis	0.00313	0.00313	CcSEcCtD
Glycopyrrolate—Tachycardia—Triamcinolone—psoriatic arthritis	0.00313	0.00313	CcSEcCtD
Glycopyrrolate—Mental disorder—Prednisone—psoriatic arthritis	0.00312	0.00312	CcSEcCtD
Glycopyrrolate—Tachycardia—Methylprednisolone—psoriatic arthritis	0.00312	0.00312	CcSEcCtD
Glycopyrrolate—Skin disorder—Methylprednisolone—psoriatic arthritis	0.00311	0.00311	CcSEcCtD
Glycopyrrolate—Malnutrition—Prednisone—psoriatic arthritis	0.0031	0.0031	CcSEcCtD
Glycopyrrolate—Erythema—Prednisone—psoriatic arthritis	0.0031	0.0031	CcSEcCtD
Glycopyrrolate—Hyperhidrosis—Triamcinolone—psoriatic arthritis	0.0031	0.0031	CcSEcCtD
Glycopyrrolate—Hyperhidrosis—Methylprednisolone—psoriatic arthritis	0.00309	0.00309	CcSEcCtD
Glycopyrrolate—Convulsion—Betamethasone—psoriatic arthritis	0.00309	0.00309	CcSEcCtD
Glycopyrrolate—Convulsion—Dexamethasone—psoriatic arthritis	0.00309	0.00309	CcSEcCtD
Glycopyrrolate—Hypertension—Betamethasone—psoriatic arthritis	0.00308	0.00308	CcSEcCtD
Glycopyrrolate—Hypertension—Dexamethasone—psoriatic arthritis	0.00308	0.00308	CcSEcCtD
Glycopyrrolate—Hypotension—Methylprednisolone—psoriatic arthritis	0.00299	0.00299	CcSEcCtD
Glycopyrrolate—Pain—Prednisolone—psoriatic arthritis	0.00298	0.00298	CcSEcCtD
Glycopyrrolate—Urinary tract disorder—Methotrexate—psoriatic arthritis	0.00294	0.00294	CcSEcCtD
Glycopyrrolate—Vision blurred—Prednisone—psoriatic arthritis	0.00292	0.00292	CcSEcCtD
Glycopyrrolate—Urethral disorder—Methotrexate—psoriatic arthritis	0.00292	0.00292	CcSEcCtD
Glycopyrrolate—Anaphylactic shock—Dexamethasone—psoriatic arthritis	0.00291	0.00291	CcSEcCtD
Glycopyrrolate—Anaphylactic shock—Betamethasone—psoriatic arthritis	0.00291	0.00291	CcSEcCtD
Glycopyrrolate—Oedema—Dexamethasone—psoriatic arthritis	0.00291	0.00291	CcSEcCtD
Glycopyrrolate—Oedema—Betamethasone—psoriatic arthritis	0.00291	0.00291	CcSEcCtD
Glycopyrrolate—Insomnia—Triamcinolone—psoriatic arthritis	0.0029	0.0029	CcSEcCtD
Glycopyrrolate—Insomnia—Methylprednisolone—psoriatic arthritis	0.00289	0.00289	CcSEcCtD
Glycopyrrolate—Infection—Dexamethasone—psoriatic arthritis	0.00289	0.00289	CcSEcCtD
Glycopyrrolate—Infection—Betamethasone—psoriatic arthritis	0.00289	0.00289	CcSEcCtD
Glycopyrrolate—Feeling abnormal—Prednisolone—psoriatic arthritis	0.00287	0.00287	CcSEcCtD
Glycopyrrolate—Nervous system disorder—Betamethasone—psoriatic arthritis	0.00285	0.00285	CcSEcCtD
Glycopyrrolate—Nervous system disorder—Dexamethasone—psoriatic arthritis	0.00285	0.00285	CcSEcCtD
Glycopyrrolate—Agitation—Prednisone—psoriatic arthritis	0.00285	0.00285	CcSEcCtD
Glycopyrrolate—Tachycardia—Dexamethasone—psoriatic arthritis	0.00284	0.00284	CcSEcCtD
Glycopyrrolate—Tachycardia—Betamethasone—psoriatic arthritis	0.00284	0.00284	CcSEcCtD
Glycopyrrolate—Dyspepsia—Triamcinolone—psoriatic arthritis	0.00282	0.00282	CcSEcCtD
Glycopyrrolate—Dyspepsia—Methylprednisolone—psoriatic arthritis	0.00281	0.00281	CcSEcCtD
Glycopyrrolate—Hyperhidrosis—Dexamethasone—psoriatic arthritis	0.00281	0.00281	CcSEcCtD
Glycopyrrolate—Hyperhidrosis—Betamethasone—psoriatic arthritis	0.00281	0.00281	CcSEcCtD
Glycopyrrolate—Urticaria—Prednisolone—psoriatic arthritis	0.00277	0.00277	CcSEcCtD
Glycopyrrolate—Cardiac disorder—Methotrexate—psoriatic arthritis	0.00276	0.00276	CcSEcCtD
Glycopyrrolate—Fatigue—Triamcinolone—psoriatic arthritis	0.00276	0.00276	CcSEcCtD
Glycopyrrolate—Fatigue—Methylprednisolone—psoriatic arthritis	0.00276	0.00276	CcSEcCtD
Glycopyrrolate—Pain—Triamcinolone—psoriatic arthritis	0.00274	0.00274	CcSEcCtD
Glycopyrrolate—Hypotension—Dexamethasone—psoriatic arthritis	0.00272	0.00272	CcSEcCtD
Glycopyrrolate—Hypotension—Betamethasone—psoriatic arthritis	0.00272	0.00272	CcSEcCtD
Glycopyrrolate—Convulsion—Prednisone—psoriatic arthritis	0.00269	0.00269	CcSEcCtD
Glycopyrrolate—Mediastinal disorder—Methotrexate—psoriatic arthritis	0.00268	0.00268	CcSEcCtD
Glycopyrrolate—Hypertension—Prednisone—psoriatic arthritis	0.00268	0.00268	CcSEcCtD
Glycopyrrolate—Feeling abnormal—Triamcinolone—psoriatic arthritis	0.00264	0.00264	CcSEcCtD
Glycopyrrolate—Feeling abnormal—Methylprednisolone—psoriatic arthritis	0.00263	0.00263	CcSEcCtD
Glycopyrrolate—Insomnia—Betamethasone—psoriatic arthritis	0.00263	0.00263	CcSEcCtD
Glycopyrrolate—Insomnia—Dexamethasone—psoriatic arthritis	0.00263	0.00263	CcSEcCtD
Glycopyrrolate—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriatic arthritis	0.00262	0.00262	CcSEcCtD
Glycopyrrolate—Gastrointestinal pain—Methylprednisolone—psoriatic arthritis	0.00261	0.00261	CcSEcCtD
Glycopyrrolate—Mental disorder—Methotrexate—psoriatic arthritis	0.00261	0.00261	CcSEcCtD
Glycopyrrolate—Malnutrition—Methotrexate—psoriatic arthritis	0.00259	0.00259	CcSEcCtD
Glycopyrrolate—Erythema—Methotrexate—psoriatic arthritis	0.00259	0.00259	CcSEcCtD
Glycopyrrolate—Hypersensitivity—Prednisolone—psoriatic arthritis	0.00257	0.00257	CcSEcCtD
Glycopyrrolate—Dyspepsia—Dexamethasone—psoriatic arthritis	0.00256	0.00256	CcSEcCtD
Glycopyrrolate—Dyspepsia—Betamethasone—psoriatic arthritis	0.00256	0.00256	CcSEcCtD
Glycopyrrolate—Urticaria—Triamcinolone—psoriatic arthritis	0.00255	0.00255	CcSEcCtD
Glycopyrrolate—Urticaria—Methylprednisolone—psoriatic arthritis	0.00254	0.00254	CcSEcCtD
Glycopyrrolate—Dysgeusia—Methotrexate—psoriatic arthritis	0.00254	0.00254	CcSEcCtD
Glycopyrrolate—Body temperature increased—Triamcinolone—psoriatic arthritis	0.00253	0.00253	CcSEcCtD
Glycopyrrolate—Oedema—Prednisone—psoriatic arthritis	0.00253	0.00253	CcSEcCtD
Glycopyrrolate—Anaphylactic shock—Prednisone—psoriatic arthritis	0.00253	0.00253	CcSEcCtD
Glycopyrrolate—Abdominal pain—Methylprednisolone—psoriatic arthritis	0.00253	0.00253	CcSEcCtD
Glycopyrrolate—Infection—Prednisone—psoriatic arthritis	0.00252	0.00252	CcSEcCtD
Glycopyrrolate—Gastrointestinal disorder—Dexamethasone—psoriatic arthritis	0.00251	0.00251	CcSEcCtD
Glycopyrrolate—Gastrointestinal disorder—Betamethasone—psoriatic arthritis	0.00251	0.00251	CcSEcCtD
Glycopyrrolate—Fatigue—Dexamethasone—psoriatic arthritis	0.00251	0.00251	CcSEcCtD
Glycopyrrolate—Fatigue—Betamethasone—psoriatic arthritis	0.00251	0.00251	CcSEcCtD
Glycopyrrolate—Pain—Betamethasone—psoriatic arthritis	0.00249	0.00249	CcSEcCtD
Glycopyrrolate—Pain—Dexamethasone—psoriatic arthritis	0.00249	0.00249	CcSEcCtD
Glycopyrrolate—Nervous system disorder—Prednisone—psoriatic arthritis	0.00248	0.00248	CcSEcCtD
Glycopyrrolate—Tachycardia—Prednisone—psoriatic arthritis	0.00247	0.00247	CcSEcCtD
Glycopyrrolate—Skin disorder—Prednisone—psoriatic arthritis	0.00246	0.00246	CcSEcCtD
Glycopyrrolate—Hyperhidrosis—Prednisone—psoriatic arthritis	0.00245	0.00245	CcSEcCtD
Glycopyrrolate—Vision blurred—Methotrexate—psoriatic arthritis	0.00244	0.00244	CcSEcCtD
Glycopyrrolate—Feeling abnormal—Betamethasone—psoriatic arthritis	0.0024	0.0024	CcSEcCtD
Glycopyrrolate—Feeling abnormal—Dexamethasone—psoriatic arthritis	0.0024	0.0024	CcSEcCtD
Glycopyrrolate—Gastrointestinal pain—Dexamethasone—psoriatic arthritis	0.00238	0.00238	CcSEcCtD
Glycopyrrolate—Gastrointestinal pain—Betamethasone—psoriatic arthritis	0.00238	0.00238	CcSEcCtD
Glycopyrrolate—Hypersensitivity—Triamcinolone—psoriatic arthritis	0.00236	0.00236	CcSEcCtD
Glycopyrrolate—Hypersensitivity—Methylprednisolone—psoriatic arthritis	0.00236	0.00236	CcSEcCtD
Glycopyrrolate—Urticaria—Dexamethasone—psoriatic arthritis	0.00231	0.00231	CcSEcCtD
Glycopyrrolate—Urticaria—Betamethasone—psoriatic arthritis	0.00231	0.00231	CcSEcCtD
Glycopyrrolate—Dizziness—Prednisolone—psoriatic arthritis	0.0023	0.0023	CcSEcCtD
Glycopyrrolate—Asthenia—Triamcinolone—psoriatic arthritis	0.0023	0.0023	CcSEcCtD
Glycopyrrolate—Abdominal pain—Dexamethasone—psoriatic arthritis	0.0023	0.0023	CcSEcCtD
Glycopyrrolate—Abdominal pain—Betamethasone—psoriatic arthritis	0.0023	0.0023	CcSEcCtD
Glycopyrrolate—Body temperature increased—Dexamethasone—psoriatic arthritis	0.0023	0.0023	CcSEcCtD
Glycopyrrolate—Body temperature increased—Betamethasone—psoriatic arthritis	0.0023	0.0023	CcSEcCtD
Glycopyrrolate—Asthenia—Methylprednisolone—psoriatic arthritis	0.00229	0.00229	CcSEcCtD
Glycopyrrolate—Insomnia—Prednisone—psoriatic arthritis	0.00229	0.00229	CcSEcCtD
Glycopyrrolate—Pruritus—Triamcinolone—psoriatic arthritis	0.00227	0.00227	CcSEcCtD
Glycopyrrolate—Pruritus—Methylprednisolone—psoriatic arthritis	0.00226	0.00226	CcSEcCtD
Glycopyrrolate—Convulsion—Methotrexate—psoriatic arthritis	0.00225	0.00225	CcSEcCtD
Glycopyrrolate—Dyspepsia—Prednisone—psoriatic arthritis	0.00223	0.00223	CcSEcCtD
Glycopyrrolate—Rash—Prednisolone—psoriatic arthritis	0.0022	0.0022	CcSEcCtD
Glycopyrrolate—Dermatitis—Prednisolone—psoriatic arthritis	0.00219	0.00219	CcSEcCtD
Glycopyrrolate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriatic arthritis	0.00219	0.00219	CcSEcCtD
Glycopyrrolate—Fatigue—Prednisone—psoriatic arthritis	0.00218	0.00218	CcSEcCtD
Glycopyrrolate—Headache—Prednisolone—psoriatic arthritis	0.00218	0.00218	CcSEcCtD
Glycopyrrolate—Constipation—Prednisone—psoriatic arthritis	0.00217	0.00217	CcSEcCtD
Glycopyrrolate—Confusional state—Methotrexate—psoriatic arthritis	0.00213	0.00213	CcSEcCtD
Glycopyrrolate—Dizziness—Triamcinolone—psoriatic arthritis	0.00212	0.00212	CcSEcCtD
Glycopyrrolate—Anaphylactic shock—Methotrexate—psoriatic arthritis	0.00212	0.00212	CcSEcCtD
Glycopyrrolate—Dizziness—Methylprednisolone—psoriatic arthritis	0.00211	0.00211	CcSEcCtD
Glycopyrrolate—Infection—Methotrexate—psoriatic arthritis	0.0021	0.0021	CcSEcCtD
Glycopyrrolate—Feeling abnormal—Prednisone—psoriatic arthritis	0.00209	0.00209	CcSEcCtD
Glycopyrrolate—Asthenia—Betamethasone—psoriatic arthritis	0.00209	0.00209	CcSEcCtD
Glycopyrrolate—Asthenia—Dexamethasone—psoriatic arthritis	0.00209	0.00209	CcSEcCtD
Glycopyrrolate—Nervous system disorder—Methotrexate—psoriatic arthritis	0.00208	0.00208	CcSEcCtD
Glycopyrrolate—Gastrointestinal pain—Prednisone—psoriatic arthritis	0.00207	0.00207	CcSEcCtD
Glycopyrrolate—Nausea—Prednisolone—psoriatic arthritis	0.00207	0.00207	CcSEcCtD
Glycopyrrolate—Pruritus—Dexamethasone—psoriatic arthritis	0.00206	0.00206	CcSEcCtD
Glycopyrrolate—Pruritus—Betamethasone—psoriatic arthritis	0.00206	0.00206	CcSEcCtD
Glycopyrrolate—Skin disorder—Methotrexate—psoriatic arthritis	0.00206	0.00206	CcSEcCtD
Glycopyrrolate—Hyperhidrosis—Methotrexate—psoriatic arthritis	0.00205	0.00205	CcSEcCtD
Glycopyrrolate—Vomiting—Triamcinolone—psoriatic arthritis	0.00204	0.00204	CcSEcCtD
Glycopyrrolate—Vomiting—Methylprednisolone—psoriatic arthritis	0.00203	0.00203	CcSEcCtD
Glycopyrrolate—Rash—Triamcinolone—psoriatic arthritis	0.00202	0.00202	CcSEcCtD
Glycopyrrolate—Dermatitis—Triamcinolone—psoriatic arthritis	0.00202	0.00202	CcSEcCtD
Glycopyrrolate—Rash—Methylprednisolone—psoriatic arthritis	0.00202	0.00202	CcSEcCtD
Glycopyrrolate—Dermatitis—Methylprednisolone—psoriatic arthritis	0.00201	0.00201	CcSEcCtD
Glycopyrrolate—Urticaria—Prednisone—psoriatic arthritis	0.00201	0.00201	CcSEcCtD
Glycopyrrolate—Headache—Triamcinolone—psoriatic arthritis	0.00201	0.00201	CcSEcCtD
Glycopyrrolate—Headache—Methylprednisolone—psoriatic arthritis	0.002	0.002	CcSEcCtD
Glycopyrrolate—Abdominal pain—Prednisone—psoriatic arthritis	0.002	0.002	CcSEcCtD
Glycopyrrolate—Body temperature increased—Prednisone—psoriatic arthritis	0.002	0.002	CcSEcCtD
Glycopyrrolate—Hypotension—Methotrexate—psoriatic arthritis	0.00198	0.00198	CcSEcCtD
Glycopyrrolate—Dizziness—Dexamethasone—psoriatic arthritis	0.00192	0.00192	CcSEcCtD
Glycopyrrolate—Dizziness—Betamethasone—psoriatic arthritis	0.00192	0.00192	CcSEcCtD
Glycopyrrolate—Insomnia—Methotrexate—psoriatic arthritis	0.00191	0.00191	CcSEcCtD
Glycopyrrolate—Nausea—Triamcinolone—psoriatic arthritis	0.0019	0.0019	CcSEcCtD
Glycopyrrolate—Nausea—Methylprednisolone—psoriatic arthritis	0.0019	0.0019	CcSEcCtD
Glycopyrrolate—Somnolence—Methotrexate—psoriatic arthritis	0.00188	0.00188	CcSEcCtD
Glycopyrrolate—Hypersensitivity—Prednisone—psoriatic arthritis	0.00187	0.00187	CcSEcCtD
Glycopyrrolate—Dyspepsia—Methotrexate—psoriatic arthritis	0.00186	0.00186	CcSEcCtD
Glycopyrrolate—Vomiting—Dexamethasone—psoriatic arthritis	0.00185	0.00185	CcSEcCtD
Glycopyrrolate—Vomiting—Betamethasone—psoriatic arthritis	0.00185	0.00185	CcSEcCtD
Glycopyrrolate—Rash—Betamethasone—psoriatic arthritis	0.00183	0.00183	CcSEcCtD
Glycopyrrolate—Rash—Dexamethasone—psoriatic arthritis	0.00183	0.00183	CcSEcCtD
Glycopyrrolate—Dermatitis—Betamethasone—psoriatic arthritis	0.00183	0.00183	CcSEcCtD
Glycopyrrolate—Dermatitis—Dexamethasone—psoriatic arthritis	0.00183	0.00183	CcSEcCtD
Glycopyrrolate—Gastrointestinal disorder—Methotrexate—psoriatic arthritis	0.00183	0.00183	CcSEcCtD
Glycopyrrolate—Fatigue—Methotrexate—psoriatic arthritis	0.00182	0.00182	CcSEcCtD
Glycopyrrolate—Headache—Dexamethasone—psoriatic arthritis	0.00182	0.00182	CcSEcCtD
Glycopyrrolate—Headache—Betamethasone—psoriatic arthritis	0.00182	0.00182	CcSEcCtD
Glycopyrrolate—Asthenia—Prednisone—psoriatic arthritis	0.00182	0.00182	CcSEcCtD
Glycopyrrolate—Pain—Methotrexate—psoriatic arthritis	0.00181	0.00181	CcSEcCtD
Glycopyrrolate—Pruritus—Prednisone—psoriatic arthritis	0.00179	0.00179	CcSEcCtD
Glycopyrrolate—Feeling abnormal—Methotrexate—psoriatic arthritis	0.00174	0.00174	CcSEcCtD
Glycopyrrolate—Gastrointestinal pain—Methotrexate—psoriatic arthritis	0.00173	0.00173	CcSEcCtD
Glycopyrrolate—Nausea—Dexamethasone—psoriatic arthritis	0.00173	0.00173	CcSEcCtD
Glycopyrrolate—Nausea—Betamethasone—psoriatic arthritis	0.00173	0.00173	CcSEcCtD
Glycopyrrolate—Urticaria—Methotrexate—psoriatic arthritis	0.00168	0.00168	CcSEcCtD
Glycopyrrolate—Dizziness—Prednisone—psoriatic arthritis	0.00167	0.00167	CcSEcCtD
Glycopyrrolate—Abdominal pain—Methotrexate—psoriatic arthritis	0.00167	0.00167	CcSEcCtD
Glycopyrrolate—Body temperature increased—Methotrexate—psoriatic arthritis	0.00167	0.00167	CcSEcCtD
Glycopyrrolate—Vomiting—Prednisone—psoriatic arthritis	0.00161	0.00161	CcSEcCtD
Glycopyrrolate—Rash—Prednisone—psoriatic arthritis	0.0016	0.0016	CcSEcCtD
Glycopyrrolate—Dermatitis—Prednisone—psoriatic arthritis	0.00159	0.00159	CcSEcCtD
Glycopyrrolate—Headache—Prednisone—psoriatic arthritis	0.00159	0.00159	CcSEcCtD
Glycopyrrolate—Hypersensitivity—Methotrexate—psoriatic arthritis	0.00156	0.00156	CcSEcCtD
Glycopyrrolate—Asthenia—Methotrexate—psoriatic arthritis	0.00152	0.00152	CcSEcCtD
Glycopyrrolate—Nausea—Prednisone—psoriatic arthritis	0.0015	0.0015	CcSEcCtD
Glycopyrrolate—Pruritus—Methotrexate—psoriatic arthritis	0.0015	0.0015	CcSEcCtD
Glycopyrrolate—Dizziness—Methotrexate—psoriatic arthritis	0.0014	0.0014	CcSEcCtD
Glycopyrrolate—Vomiting—Methotrexate—psoriatic arthritis	0.00135	0.00135	CcSEcCtD
Glycopyrrolate—Rash—Methotrexate—psoriatic arthritis	0.00133	0.00133	CcSEcCtD
Glycopyrrolate—Dermatitis—Methotrexate—psoriatic arthritis	0.00133	0.00133	CcSEcCtD
Glycopyrrolate—Headache—Methotrexate—psoriatic arthritis	0.00133	0.00133	CcSEcCtD
Glycopyrrolate—Nausea—Methotrexate—psoriatic arthritis	0.00126	0.00126	CcSEcCtD
